CONMED (US:CNMD)2026-01-28 22:32Financial Data and Key Metrics Changes - Total sales for Q4 2025 were $373.2 million, a year-over-year increase of 7.9% as reported and 7.1% in constant currency [6] - Full year sales reached $1.375 billion, representing a year-over-year growth of 5.2% as reported and 5.1% in constant currency [6] - Adjusted earnings per share (EPS) for Q4 was $1.43, growing 6.7%, while full year adjusted EPS was $4.59, an increase of 10.1% [6][23] Business Line Data and Key Metrics Changes - Orthopedic sales increased by 12.1% in Q4 and 5.5% for the full year on a constant currency basis [6] - General surgery sales grew by 3.8% in Q4 and 4.7% for the full year in constant currency [6] - U.S. orthopedic sales grew 6.6%, while international orthopedic sales increased 15.7% in Q4 [17] - U.S. general surgery sales declined 0.4%, while international sales increased 14.8% in Q4 [18] Market Data and Key Metrics Changes - International sales grew 15.4% in Q4, while U.S. sales increased by 1.4% [17] - The U.S. market for general surgery faced challenges due to portfolio management and strategic focus on growth drivers [18] Company Strategy and Development Direction - The company plans to exit the gastroenterology product lines to focus on high-growth, high-margin markets such as robotic and laparoscopic surgery [7][8] - The strategy includes stabilizing and scaling operations to build a high-performance supply chain [9] - The company aims to achieve above-market growth by investing in key growth platforms and normalizing supply in sports medicine [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver sustained above-market growth through operational improvements and strategic focus [15] - The company is optimistic about the growth potential of its AirSeal and BioBrace platforms, with expectations of high single-digit to low double-digit growth rates [10][13] Other Important Information - The company suspended its dividend and approved a $150 million share repurchase authorization [15] - The leverage ratio at the end of Q4 was 2.9 times, providing flexibility for innovation and growth [24] Q&A Session Summary Question: Can you discuss the cadence for the rest of the year and any selling day differences? - Management indicated no selling day differences and expected normal seasonality for the med tech calendar [32] Question: What is the status of the CFO search? - The company is actively searching for a new CFO who will focus on shareholder value and be a strong team player [34] Question: Can you clarify the organic revenue numbers presented at the healthcare conference? - The difference in organic revenue numbers was due to final adjustments in the base numbers as the year progressed [37] Question: What drove the upside in orthopedic sales and the downside in general surgery? - The orthopedic sales benefited from a committed sales force and improved supply chain, while general surgery faced challenges due to portfolio management [41][42] Question: How will the GI business be reported going forward? - The GI business will be reported separately, reflecting its exit from the main revenue figures [54] Question: What are the growth trends for AirSeal internationally? - AirSeal continues to perform within expected growth ranges, with opportunities in both laparoscopic and robotic procedures [68]